Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Total Non-Current Liabilities: 2023

  • Immunome's Total Non-Current Liabilities was N/A to $27.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $27.3 million, marking a year-over-year change of. This contributed to the annual value of $27.3 million for FY2023, which is N/A change from last year.
  • As of Q4 2023, Immunome's Total Non-Current Liabilities stood at $27.3 million, which was down 68.59% from $87.0 million recorded in Q3 2023.
  • In the past 5 years, Immunome's Total Non-Current Liabilities registered a high of $87.0 million during Q3 2023, and its lowest value of $27.3 million during Q4 2023.
  • For the 1-year period, Immunome's Total Non-Current Liabilities averaged around $57.1 million, with its median value being $57.1 million (2023).